This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| The LOX | |
|---|---|
| Name | LOX |
| Chromosome | 5q23.3 |
The LOX The LOX enzyme is a copper-dependent amine oxidase implicated in extracellular matrix maturation, tissue morphogenesis, and disease processes. First characterized in biochemical studies of connective tissue, LOX has been examined across research on Collagen, Elastin, Fibronectin, Transforming growth factor beta, and Tumor necrosis factor. LOX-related pathways intersect with signaling cascades involving Hypoxia-inducible factor 1-alpha, Matrix metalloproteinase 2, and Integrin beta1 in contexts ranging from Wound healing to Metastasis.
LOX was initially identified through biochemical fractionation of Bone and Aorta extracts and later cloned from human and murine cDNA libraries alongside paralogs characterized as LOXL1, LOXL2, LOXL3, and LOXL4. The gene resides on Chromosome 5 (human), and its protein product is synthesized as a ~50 kDa proenzyme that undergoes extracellular proteolytic processing by proteases such as Bone morphogenetic protein 1 and related metalloproteases. LOX activity requires a copper cofactor coordinated by conserved histidine residues and a lysyl tyrosylquinone (LTQ) cofactor formed post-translationally.
LOX is a single-chain, secreted amine oxidase with an N-terminal signal peptide and a C-terminal catalytic domain. The enzyme contains consensus copper-binding motifs homologous to those in Copper amine oxidase family members and shares structural features with the AOC1 subgroup. LOX biogenesis involves translation on rough endoplasmic reticulum associated ribosomes, N-linked glycosylation in the Golgi apparatus, and secretion into the extracellular space where proteolytic cleavage by proteases related to Furin and BMP1 releases an active mature enzyme and an N-terminal propeptide (LOX-PP) with independent biological activities. Copper uptake for LOX maturation is coordinated with copper chaperones such as ATOX1 and transporters including CTR1.
LOX catalyzes oxidative deamination of specific lysine and hydroxylysine residues in Collagen and Elastin, forming reactive aldehydes that spontaneously cross-link to stabilize extracellular matrices in tissues like Skin, Lung, Heart, and Tendon. Cross-linking mediated by LOX influences mechanical properties relevant to Aneurysm susceptibility, Fibrosis progression, and organ development regulated by factors such as Sonic hedgehog and Notch signaling pathway components. LOX activity is regulated transcriptionally by factors including Hypoxia-inducible factor 1-alpha under hypoxic conditions, post-translationally by glycosylation and proteolytic activation, and inhibited by endogenous molecules like β-aminopropionitrile and synthetic inhibitors modeled after substrates. In addition to extracellular actions, the LOX propeptide and intracellular LOX isoforms modulate cell behavior through interactions with proteins such as p53, c-Jun, and Focal adhesion kinase influencing processes observed in Embryogenesis and Angiogenesis.
Dysregulated LOX expression and activity are implicated in a spectrum of human disorders. Elevated LOX is associated with tumor invasion and metastasis in cancers including Breast cancer, Colorectal cancer, Pancreatic cancer, and Glioblastoma multiforme by remodeling peritumoral stroma and promoting pre-metastatic niche formation involving Bone marrow-derived cells. Conversely, LOX deficiency or loss-of-function mutations contribute to connective tissue fragility syndromes presenting with cutaneous laxity and vascular anomalies such as familial forms of Aortic aneurysm and Ehlers–Danlos syndrome-like phenotypes. LOX also plays roles in chronic fibrotic diseases affecting Pulmonary fibrosis, Liver cirrhosis, and Systemic sclerosis where interactions with profibrotic mediators like Transforming growth factor beta exacerbate matrix deposition. Pharmacologic modulation of LOX activity is therefore of interest in oncology, cardiology, and fibrotic disease management.
LOX expression is routinely assayed by techniques such as immunohistochemistry using antibodies recognizing mature LOX or LOX-PP on tissue sections from Human tissue banks, Western blotting in cell lysates, and quantitative PCR for LOX mRNA in clinical samples. Enzymatic activity can be measured using fluorometric and colorimetric assays that detect hydrogen peroxide generation or aldehyde products after incubation of LOX with substrates derived from Collagen or synthetic amine substrates; assays often employ horseradish peroxidase coupling or Amplex Red reagents. Mass spectrometry and cross-link quantitation analyze LOX-mediated modifications in extracellular matrix proteomics studies leveraging platforms developed for Proteomics research. Noninvasive imaging probes targeting LOX activity have been explored in preclinical models using radiolabeled inhibitors and molecular imaging modalities compatible with Positron emission tomography and Magnetic resonance imaging.
Therapeutic strategies targeting LOX include small-molecule inhibitors, monoclonal antibodies, and approaches modulating copper availability via chelators like Tetrathiomolybdate. In oncology, LOX inhibition aims to reduce metastasis and enhance delivery of chemotherapeutics in combination with agents such as Paclitaxel or Doxorubicin. Antifibrotic interventions targeting LOX are under investigation alongside antifibrotic agents like Pirfenidone and Nintedanib. LOX propeptide derivatives are being explored for their tumor-suppressive properties in preclinical models involving Xenograft systems. Research tools include genetically engineered mouse models with targeted LOX deletion or overexpression, CRISPR/Cas9-mediated editing applied in cell lines, and high-content screening platforms integrating LOX activity readouts for drug discovery.
Category:Enzymes